Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Granted Marketing Approval in Mainland China for NERLYNX (neratinib)
Go back to Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Granted Marketing Approval in Mainland China for NERLYNX (neratinib)| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 7.66 +0.10 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.56 | 52 Week High | $82.81 | |||
| Open | $7.60 | 52 Week Low | $19.74 | |||
| Day High | $7.87 | P/E | N/A | |||
| Day Low | $7.56 | EPS | $-2.16 | |||
| Volume | 379,123 | |||||
